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Abstract
Background: Because of the potentially significant economic burden of healthcare costs associated with many diseases, it is
critical that regulatory and medical insurance organisations collect and utilise data on the cost-effectiveness of care
provision to make rational policy decisions. However, little is known about healthcare costs in China.
Methodology/Principal Findings: Based on health expenditure data for 253 cases of advanced non-small cell lung cancer
(NSCLC) registered at the Second Xiangya Hospital of Central South University in China between 2006 and 2010, the cost of
care provision was analysed. The monthly and aggregate annual medical costs were estimated for patients who were in
either a progression-free state (PFS) or a disease-progression state (DPS). Monthly healthcare costs accumulated during the
terminal 3 months were collected separately. The mean cost of treatment for PFS and DPS patients over one year was
approximately US$11,566 and $14,519, respectively. The monthly costs for all patients were higher initially than in the
subsequent months (PFS: $2,490; DPS: $2,503). For PFS patients, healthcare expenditures stabilised after the 7th month, with
a mean monthly medical expenditure of $82.49. For DPS patients, expenditures stabilised after the 9th month, and the mean
expenditure during the 9th month was $307.9. Medical care costs in the three successive months prior to death were $3,754,
$5,829 and $7,372, respectively.
Conclusions/Significance: The economic evaluation of health care technologies is becoming ever more important in China,
especially in disease areas for which new and expensive therapies are being introduced on a regular basis. This is first paper
to present empirically estimated China-specific costs associated with the treatment of NSCLC. The cost estimates are
presented in a format that is specifically intended to inform cost-effectiveness analyses of treatments for NSCLC, and hence,
contribute to the more efficient allocation of limited healthcare resources in China.
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Introduction
Lung cancer, the most commonly diagnosed form of cancer, is
also the deadliest form of cancer in males [1]. There has been a
continuous decline in lung cancer death rates in most Western
countries [2]. However, in developing countries, such as China
and other Asian, and African countries, the rates are increasing
[2]. Consequently, lung cancer is becoming an increasingly
significant public health problem in China [3]. Non-small cell
lung cancer (NSCLC) accounts for more than 85% of all lung
cancer cases [4], approximately 40% of which are first diagnosed
at the advanced stage of malignancy [5]. Healthcare spending for
NSCLC has increased because of the growing number of new
therapies [6], including third-generation chemotherapies and
molecular targeted drugs (angiogenesis inhibitors, tyrosine-kinase
inhibitors, and pemetrexed, a folate antimetabolite) [5,7,8].
Because of the significant economic burden that patients often
bear as a result of their healthcare costs, it is critical that regulatory
and medical insurance organisations collect and utilise data to
estimate the cost-effectiveness of alternative options for the
provision of health care [9]. Mathematical models that can
estimate the long-term cost-effectiveness of alternative strategies
using available data, while making some necessary and appropri-
ate assumptions are now commonly utilised to guide policy
decision-making [10,11]. Such models comprise health states,
through which a cohort of hypothetical patients may progress over
the remainder of their modelled lifetime. However, to populate the
model parameters associated with the time spent in each of the
defined model states requires data on patients’ health status over
time and associated data on healthcare expenditures and quality of
life [12]. Unfortunately, these parameters are often difficult to
estimate due to a lack of available and current data, especially in
China, a developing country where the field of pharmacoeco-
nomics remains in its infancy [13].
The aim of this research, from the perspective of the Chinese
healthcare system, was to inform patients and oncologists about
the healthcare costs associated with treating advanced NSCLC,
including more specialised knowledge about the time- and health
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status-related medical costs that patients may anticipate. Figure 1
shows the Markov processes used by Carlson JJ et al [14] and Wu
B et al [15,16], in whom progression-free state (PFS) denotes a
steady state of disease without signs of worsening and disease-
progression state (DPS) signifies progression of the disease. Our
study had three specific objectives: first, to calculate the total costs
over a 12-month follow-up period for patients in a progression-free
state (PFS) and a disease-progression state (DPS); second, to
estimate the monthly costs following a PFS and PDS; and last, to
estimate average healthcare expenditures during the terminal
phase of the disease.
Materials and Methods
Data Collection
To conduct the analysis, two databases were designed and
created at the Second Xiangya Hospital of Central South
University in China. The databases were populated from the
medical records of 253 patients who were diagnosed with
advanced NSCLC.
A total of 5,708 patients were diagnosed with lung cancer in the
Second Xiangya Hospital’s oncology department records from
2006 to 2010. A simple random sample (n = 571), with a sampling
fraction of 10%, was generated online using an automated random
number generator (http://stattrek.com/Tables/Random.aspx). A
total of 475 of the randomly selected patients had been diagnosed
with NSCLC (the rest were SCLC), and only patients in the
advanced stage were included. Some patients who had been
diagnosed at stage I or II but who had then progressed to an
advanced stage were also included. Ultimately, 253 patients met
the inclusion criteria for our study (Figure 2). We screened all 253
of the eligible patients, including both inpatients and outpatients.
The survival time for each was split into PFS and DPS (where
relevant), and data for PFS and DPS were added to two separate
databases. The PFS database contained 228 patients, and the DPS
database contained 104 patients. We populated the two databases
as thoroughly as possible using case records from the medical
record library and the electronic medical record system, medical
reports from the information section (a department in the
hospital), and the Second Xiangya Hospital oncology depart-
ment’s outpatient database. Using the patient medical information
contained in the medical record library and the electronic medical
records system, all of the basic health and disease management
information for each patient was recorded on to the relevant
database, i.e. PFS or DPS, according to patient status. Through
medical reports from the information section and the oncology
outpatient database, we collected data on each patient’s use of all
healthcare-related resources from the date of diagnosis to the date
of death or his/her last clinic appointment with the oncology
department. Data on resource utilisation were collected for a
maximum of 12 months for each patient.
To estimate the monthly costs associated with PFS and DPS,
within each of the two databases, each patient’s pattern of resource
use was divided into different intervals by month in chronological
order. Monthly and annual observations were only included if a
patient remained in the same state (PFS or DPS) for the full month
or year, respectively. Expenditures on healthcare resources that
were used for more than a month (in the inpatient setting, for
example) were averaged over the total number of days utilised, and
that average value was used to calculate the mean monthly costs.
For example, one patient who was hospitalised for 40 days over a
2-month period spent 25 days of 1 month and 15 days of the
subsequent month receiving treatment. Thus, the first month’s
expenditures were calculated as 25/40 of the total cost of
hospitalisation, and the surplus (15/40) was added to the next
month’s tally.
Resource use distinguished between those incurred in inpatient
and outpatient settings. Inpatient costs reflected the cost of
hospitalisation and other related expenses, including the costs for
medicine, scans, biopsies, therapy, radiation, nursing care,
materials and ward bed. We included any outpatient costs
associated with adverse reactions and/or re-examinations.
Unit costs in this study were estimated in US dollars (USD),
corresponding to the 2010 consumer price index and assuming an
average exchange rate of 1 USD to 6.7695 Renminbi (RMB). The
majority of the unit costs were derived from the Publicity Medicine
Prices of Hunan [17], which are based on data collected from all of
the hospitals in the Hunan province of China. Unit costs that
could not be obtained from the Publicity Medicine Prices of
Hunan were collected from the Second Xiangya Hospital. The
unit cost of radiotherapy reflects the radiation fee for a single-
fraction irradiation session. Table 1 presents a selection of unit
costs.
This study was approved in accordance with the principles of
the ethics committee in the Second Xiangya Hospital of Central
South University (Changsha, People’s Republic of China). Written
consent was given by the patients for their information to be stored
in the hospital database and used for research.
Statistical Analysis
Three methods of analysis are described in the following section.
The first analysis estimates the total aggregate healthcare costs
over one year for patients with advanced NSCLC. The mean costs
were estimated and evaluated using 95% confidence intervals (CIs)
through bootstrapping with the R software (version 2.14.0; R
Development Core Team, Vienna, Austria).
The second analysis estimated the average monthly costs for
PFS and DPS patients. The purpose of this analysis was to
calculate the sequential average monthly costs for PFS and DPS
patients. The mean monthly costs over the first year following
entry to each state were estimated, and 95% CIs were generated
through a bootstrapping method.
The final analysis estimated the end-of-life healthcare costs for
63 patients. Patient health expenditures during the terminal phase,
also referred to as the end-of-life costs, are different from the costs
attributable to standard therapy [18]. For the 63 patients with
advanced NSCLC who died during the study period, costs
incurred during their last 3 months of life were collected and
analysed to estimate the mean end-of-life costs, with corresponding
bootstrapped CIs.
Figure 1. Markov process of advanced NSCLC.
doi:10.1371/journal.pone.0048323.g001
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Results
In total, 253 eligible cases were identified and assessed, and they
were classified by their PFS, DPS or terminal-stage status. The
study included 228 PFS patients, 104 DPS patients and 63
terminal phase patients.
Patient Characteristics
Table 2 shows demographic information for all of the NSCLC
patients in the random sample of advanced-stage patients. The
mean and median ages of the 253 patients were 58 and 59 years,
respectively, and the median survival time and progression-free
survival time of the patients were 10.5 and 7.0 months,
respectively. Figure 3 shows Kaplan-Meier curves for the overall
survival and progression-free survival of the enrolled patients.
The cost results are described in the following sections and
include the 1-year average costs, the monthly costs for PFS and
DPS patients, and terminal-phase expenditures. The results are
depicted with error bars, and the high and low means are
presented with 95% CIs (with the Sigma Plot Scientific
Graphing Software version 10.0; Jandel Scientific, San Rafael,
CA, USA).
Total 1-year Costs
Figure 4 shows the total 1-year costs for PFS and DPS patients
who remained alive throughout the entire year. DPS patients have
higher 1-year costs than PFS patients. The mean costs for PFS and
DPS patients were approximately $11,566 (95% CI $10,194–
$13,153) and $14,519 (95% CI $12,011–$16,871), respectively.
Monthly Costs
Monthly costs for PFS and DPS patients who remained alive
throughout the entire year are presented in Figure 5 and Figure 6.
The initial monthly treatment costs for PFS patients (mean $2,490,
95% CI $2,308–$2,702) and DPS patients (mean $2,503, 95% CI
$2,110–$2,914) are higher than the mean expenditures in
subsequent months.
The mean medical care costs for PFS patients decreased steadily
in the first 4 months, and the mean medical care expenditure in
the 4th month was $2,024 (95% CI $1,714–$2,335) for this group.
A sharp decline in expenditures occurred from the 5th to the 7th
months, and costs stabilised after the 7th month. The mean
monthly medical care expenditure from the 7th to the 12th month
was $82.49 (95% CI $73.90–$91.49). In comparison, the mean
medical care costs for DPS patients decreased steadily in the first 3
months, and the mean medical care expenditure by the 3rd month
was $2,270 (95% CI $1,910–$2,643). Subsequently, a significant
decrease in expenditures occurred in the 4th and 5th months. The
mean medical care costs for the 5th and 6th months were $9555
and $1,005, respectively (95% CIs were $442.0–$1,510 and
$503.4–$1,558, respectively). The mean monthly costs continued
to decline slowly from the 7th to the 9th month and remained
steady after the 9th month. The mean medical care costs for the 9th
to 12th months were $307.9, $376.2, $331.0, and $326.6,
respectively.
Terminal-phase Costs
Figure 7 shows the costs associated with end-of-life care
provision in patients with advanced NSCLC. The mean medical
care costs for the three successive months prior to death were
Figure 2. Flow-chat of patients enrolled.
doi:10.1371/journal.pone.0048323.g002
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$3,754, $5,829 and $7,372, respectively (95% CIs, $3,274–$4,238,
$4,922–$6,807 and $6,109–$8,695, respectively).
Discussion
This study evaluated the medical costs associated with treating
advanced NSCLC in China, estimating the mean cost of care over
the 1-year follow-up period for DPS patients ($14,519) to be higher
than for PFS patients ($11,566). There are three possible
explanations for this result. First, more patients preferred to use
tyrosine-kinase inhibitors (TKIs) once their disease progressed, and
TKI is more expensive than the standard first-line treatments.
Second, patients whose condition progressed further had no
recourse but to receive palliative care if TKI failed to halt disease
progression, and palliative care is more costly than most active
treatments. Last, traditional Chinese medicine was used more
frequently in DPS patients because its use was associated with
fewer side effects, including weakness, emesis, and anorexia.
For PFS patients, the mean monthly medical care costs
remained stable after a slight decline over the first 4 months.
Because medications were not adjusted or changed significantly
throughout the study period, the fees associated with routine tests
and lab work (which are essential in helping doctors to develop
rational patient-specific therapy regimens) largely determined any
differences in the monthly costs. In addition, responses to
chemotherapy were evaluated after every two cycles, so the costs
in the third month were slightly higher than were those in the
second month. Commonly, four to six cycles of chemotherapy
treatment over 3 to 6 months are administered for lung cancer,
and most patients do not receive further chemotherapy beyond the
4–6 cycles if they remain in a progression-free state. Any costs
associated with the conclusion of chemotherapy were related to
adverse reactions to the chemotherapy and routine examinations.
Therefore, medical care costs declined sharply after the first 4–6
months. Patients did not undergo further chemotherapy if their
condition did not warrant it, but they continued to undergo
routine examination every 2 or 3 months. Consequently, monthly
medical costs basically stabilised after the 7th month.
For DPS patients, the medical care costs declined slowly in the
first 3 months, mirroring the trend observed in the PFS group
during the first 4 months. Some patients sought palliative care if
their condition did not respond after three treatment cycles, which
led to a sharp decrease in the cost of care in the 3rd–5th months. In
the 6th month, the medical care costs were similar to the 5th
month because treatment regimens remained unchanged during
these months. In months 6–9, the costs decreased slowly, both
because some patients’ condition were under control and because
as a benefit of pharmaceutical policy, TKI was free once a patient
had received it for 5 months. During the remaining 2 months of
the analysis, costs were stable largely because a majority of patients
were receiving palliative care at this point.
Medical care costs in the three successive months prior to death
were $3,754, $5,829 and $7,372, respectively. During the terminal
phase of their disease, patients generally received only supportive
care and symptomatic treatment, such as nutrition support,
palliative and psychological care, and oftentimes the additional
services of rescue and skilled nursing facilities. The additional cost
of care in the terminal phase of the disease resulted in medical care
expenditures during the last month of life that exceeded any single
monthly expenditure for either PFS or DPS patients. Because 17
patients incurred no healthcare costs in their penultimate month of
life, the total cost of care during their last 2 months was equal to
the monthly expenditure for the 2 months prior to their death.
The same situation happened during the last three months for 22
patients. Because the terminal-phase costs were retrospectively
calculated from the total costs 3 months prior to death, inevitably,
Table 1. Unit cost of selections.
Resource Unit cost (US $)
Examination
CT chest scan 59
Enhanced CT chest 96





Three dimensional conformal RT (3DCRT) 30
Intensity Modulated RT (IMRT) 44
Chemotherapy
1 Course of TP treatment (270 mg,120 mg) 1,738
1 Course of DP treatment (120 mg,120 mg) 1,521
1 Course of GP treatment (3.6 g,120 mg) 1,632
1 Course of NP treatment (80 mg,120 mg) 716
Docetaxel (20 mg) 97
Molecular targeted therapy
Pemetrexed (200 mg) 321
Gefitinib (250 mg) 81
Erlotinib (150 mg) 95
rh endostatin (15 mg) 157
TP: paclitaxel plus cisplatin; GP: gemcitabine plus cisplatin; DP: docetaxel plus
cisplatin; NP: vinorelbine plus cisplatin.
doi:10.1371/journal.pone.0048323.t001
Table 2. Patient characteristics.








Stage I 79 –
Stage II 88 –
Stage III 117 131
Stage IV 110 122
Not known 81 –
Overall survival time (months)
Median – 10.0
Mean – 9.1
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as observed in Figure 7, the mean costs during the terminal phase
increased.
Previous studies have reported the medical costs of NSCLC but
have lacked a systematic approach for presenting cost data in a
format that is suitable for populating cost-effectiveness models. In
the United States, Kutikova reported a mean monthly treatment
cost of $6,520 per patient (year 2005 value) [19]. The average total
management costs in France were estimated to be as high as
J39,979620,279 ($55,526628,165, year 2007 value) [20]. In
Canada, Navaratnam reported that the mean cost per advanced
NSCLC patient was $10,805 and the average cost per patient-
month ranged from $1,645 to $1,792 in current prices (year 2010
value) [21]. In the Netherlands, the mean total medical cost over 1
year for each patient with advanced NSCLC was J32,840
($46,914, year 2009 value) [22]. Costs reported in these other
studies are higher than the current study. Such differences may
occur due to variation in the systems of care provision, financing
and reimbursement [23]. Looking for potential factors, we first
note that China is a developing country, where costs of medical
services and examinations are lower than that in developed
countries. It is also important to note that traditional Chinese
medicine exerts a high influence on medical care costs in China.
Traditional Chinese medicine, used widely throughout China, was
integrated into the antineoplastic care strategy in approximately
70% of the cases in this study. A more specific reason may be that
as a benefit of pharmaceutical policy in China, TKI was free once
a patient had received it for 5 months.
Chouaid et al analysed costs associated with NSCLC in France,
estimating separate three monthly costs of US$10,476 for patients
receiving first-line treatment, $6,555 for second-line treatment,
Figure 3. Progression-free survival and overall survival of patients.
doi:10.1371/journal.pone.0048323.g003
Figure 4. One-year costs (with 95%CI) of PFS without
progression and PDS remaining alive.
doi:10.1371/journal.pone.0048323.g004
Figure 5. Mean monthly costs (with 95%CI) of PFS without
progression.
doi:10.1371/journal.pone.0048323.g005
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$539 for remission, and $5764 for the no active treatment phase
for patients diagnosed with distant NSCLC [24]. Estimated from
428 patients, the mean aggregate 18 month cost was reported to
be $20,184 (95% CI $3,521 to 46,393), which is a slightly higher
per month cost than the current study, but the CI is wide. The
current study provides cost estimates that are similarly designed to
inform cost-effectiveness analyses, but from a Chinese health
system perspective, and using alternative categorisation of the
disease process, PFS versus DPS over 1 year, 1 month, and during
the final 3 months of life.
The current study had two main limitations. First, because this
study provides initial estimates, our study population was derived
from just one hospital. To comprehensively evaluate the cost of
medical care in China, it will be necessary to collect data from
more hospitals across the country. Generally, the treatment
patterns observed in the sampled NSCLC patients followed
NCCN Practice Guidelines in Oncology: Non-Small Cell Lung
Cancer (Chinese version) [25]. Thus the difference of treatment
patterns between Chinese hospitals is not expected to be
significant, especially between upper first-class hospitals. The
Second Xiangya Hospital of Central South University is a large-
scale, well-equipped (upper first-class) Chinese hospital. In Hunan
province, about one third of Lung cancer patients were treated in
this hospital. With respect to the unit cost, the cost of majority of
drugs in the same geographical area in China is the same.
Generally, the cost of drugs account for a large proportion of total
Lung cancer treatments, especially for advanced NSCLC. On the
basis of this, there is very little difference in unit cost among
hospitals in the same geographical area.
With respect to the unit costs, drugs account for a large
proportion of total lung cancer treatment costs, and the unit cost
for the majority of drugs in the same geographical area in China is
the same. Across China more generally, we would also expect only
small differences in drug costs as the government attaches great
importance to drug price policy, with a strict management system.
In addition, there is a drug market price monitoring system in
China that strengthens the oversight of drug price, which also acts
to stabilize drug costs.
Second, the available data in the hospital may not have been
sufficient to assess all of the medical costs from the time of initial
diagnosis to death. This lack of data may have influenced our
reported results, especially the terminal-phase costs. Any patients
who decided to suspend therapy or were transferred to another
hospital would have been lost to follow-up. However, in our study
only 27 patients were judged to have incomplete data (no medical
records in the hospital for more than two months before death),
which accounted for 10.7% of all enrolled patients.
This study had two key strengths. First, our data came from a
database of real clinical cases, which likely better reflected the true
medical care costs for patients. Second, the format of the presented
results will be useful for Chinese health economists undertaking
further economic analyses, including the use of mathematical
modelling in evaluating the cost-effectiveness of treating advanced
NSCLC.
Despite these limitations, the costs estimated in this study
provide compelling evidence of the significant costs associated with
the treatment of advanced NSCLC. The relevance and value of
the presented cost data is demonstrated by the frequency with new
therapies for the treatment of NSCLC are introduced. In recent
years, five prospective randomised clinical trials showed clinical
benefits for erlotinib [26,27] and gefitinib [28–30] in EGFR
mutation-positive NSCLC, pemetrexed had demonstrated superi-
or general efficacy to a range of comparators [31–34], and in
patients with advanced NSCLC, rh-endostatin plus platinum-
based chemotherapy has shown significantly longer PFS [35,36].
All of these new treatments are more costly than the therapies they
are designed to replace, and so cost-effectiveness analyses are
required to make funding decisions. Unfortunately, costs associ-
ated with those treatments are often difficult to estimate due to a
lack of available and current data, especially in China, where the
development of pharmacoeconomics is slow. The costing data
provided by our study will be of great value to these cost-
effectiveness analyses.
In conclusion, the economic evaluation of health care technol-
ogies is becoming ever more important in China, especially in
disease areas for which new and expensive therapies are being
introduced on a regular basis, such as NSCLC. This is first paper
to present empirically estimated China-specific costs associated
with the treatment of NSCLC by disease stage, in a format that is
specifically intended to inform cost-effectiveness analyses of
treatments for NSCLC, and hence, contribute to the more
efficient allocation of limited healthcare resources in China.
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